| Study | Exclusion reasons | Rmk | Reference |
|---|---|---|---|
| Daskalakis, 2017 | inadequate or absent control group | EXCLUDED: the 2 groups were exposed to the same antibiotic regimen (amoxicillin and metronidazole), with or without probiotics. Lack of unexposed metronidazole group. |
Daskalakis Fetal. Diagn. Ther. 2017; 42:92-98 10.1159/000450995 |
| Mitchell a, 2009 | inadequate or absent control group | EXCLUDED: oral versus vaginal metronidazole => all groups treated => no adequate control group. | |
| Lazenby, 2019 | inadequate or absent control group | EXCLUDED: 'The majority of subjects were prescribed either single-dose (n = 352) or multidose metronidazole (n = 74).' No analysis between treated and untreated women. |
Lazenby Sex Transm Dis 2019; 46:2-8 10.1097/OLQ.0000000000000902 |
| Lee, 2016 | inadequate or absent control group | EXCLUDED: The 2 groups included pregnant women exposed to Metronidazole. Regimen 1: ampicillin and/or cephalosporins (n=195), and metronidazole in 15 patients. Regimen 2: ceftriaxone, clarithromycin, and metronidazole. |
Lee J. Matern. Fetal. Neonatal. Med. 2016; 29:707-20 10.3109/14767058.2015.1020293 |
| Kissinger, 2018 | inadequate or absent control group | EXCLUDED: all patients treated with metronidazole => inadequate control group. |
Kissinger Lancet Infect Dis 2018; 18:1251-1259 10.1016/S1473-3099(18)30423-7 |
| Rana, 2014 | inadequate or absent control group | EXCLUDED: all patients treated with prophylactic antibiotics. |
Rana, M. International Journal of Infertility and Fetal Medicine 2014; 5:18-. 10.5005/jp-journals-10016-1075 |
| Ijarotimi, 2013 | inadequate or absent control group | EXCLUDED: all groups treated with metronidazole (short versus long term antibiotic prophylaxis). No adequate control group. | |
| Scott-Gray, 1964 | inadequate or absent control group | EXCLUDED: all pregnant women exposed to Metronidazole. No unexposed control group. |
Scott-Gray J Obstet Gynaecol Br Commonw 1964; 71:82-5 10.1111/j.1471-0528.1964.tb04246.x |
| Rodin, 1966 | inadequate or absent control group | EXCLUDED: all pregnant women exposed to Metronidazole. No unexposed control group. | |
| Peterson, 1966 | inadequate or absent control group | EXCLUDED: all pregnant women exposed to Metronidazole. No unexposed control group. | |
| Yudin, 2003 | inadequate or absent control group | EXCLUDED: all patients treated with metronidazole (oral or vaginal) => Lack of unexposed group. Furthermore no relevant outcomes. |
Yudin Obstet Gynecol 2003; 102:527-34 10.1016/s0029-7844(03)00566-0 |
| Westen, 2015 | inadequate or absent control group | EXCLUDED: all patients exposed to Metronidazole (Single-dose versus multiple day dose). Lack of unexposed control group. |
Westen Acta Obstet Gynecol Scand 2015; 94:43-9 10.1111/aogs.12517 |
| Peterson, 1966 | inadequate or absent control group | EXCLUDED: all pregnant women exposed to metronidazole. No unexposed group. | |
| Fouks, 2018 | case report or case series | EXCLUDED: one case of stillbirth after Metronidazole and Gentamicin treatment. | |
| Ingemarsson, 2005 | case report or case series | EXCLUDED: All cases were also treated with antibiotics (metronidazole and cefuroxime intravenously). |
Ingemarsson BJOG 2005; 112 Suppl 1:89-93 10.1111/j.1471-0528.2005.00593.x |
| Robinson, 1965 | case report or case series | EXCLUDED: outcomes of pregnancies only provided for women exposed to metronidazole. No unexposed control group. | |
| Grubor, 2018 | other reason | EXCLUDED: for metronidazole there were no data related to safety neonate outcome ('any developmental disorder in the offspring'). |
Grubor, I. Acta Poloniae Pharmaceutica - Drug Research 2018; 75:1439-. 10.32383/appdr/90828 |
| Ross, 1983 | other reason | EXCLUDED: Outcomes (birth weight and gestational age at delivery) studied as continuous variables. | |
| Grubor, 2018 | other reason | EXCLUDED: for metronidazole there were no data related to safety neonate outcome ('any developmental disorder in the offspring'). |
Grubor, I. Acta Poloniae Pharmaceutica - Drug Research 2018; 75:1439-. 10.32383/appdr/90828 |
| Obi, 2007 | not relevant exposure | EXCLUDED: no data on the treatment ('antibiotic administration', NOS). |
Obi J Obstet Gynaecol 2007; 27:37-40 10.1080/01443610601016875 |
| Persaud, 2015 | not relevant exposure | EXCLUDED: No exposure to Metronidazole intrapartum (4 exposures post delivery). Outcomes studies for antibiotic as a whole without distinction between treatments. |
Persaud J. Matern. Fetal. Neonatal. Med. 2015; 28:1190-5 10.3109/14767058.2014.947578 |
| Eleje, 2014 | not relevant exposure | EXCLUDED: Study related to the sensitivity to antibiotic drugs among isolated bacteria in the PPROM group. The sensitivity of the bacterial isolates to metronidazole was not tested in the present study. |
Eleje Int J Gynaecol Obstet 2014; 127:10-4 10.1016/j.ijgo.2014.04.016 |
| Lopez, 2005 | not relevant exposure | EXCLUDED: Analysis of periodontal therapy consisted of plaque control instructions, supra- and subgingival scaling, and crown polishing. Metronidazole could be used for women with vaginosis but no analysis of these group of women. |
Lopez J. Periodontol. 2005; 76:2144-53 10.1902/jop.2005.76.11-S.2144 |
| Steyn, 2003 | not relevant exposure | EXCLUDED: no exposure to metronidazole (exposure to vitamin C or a matching placebo). |
Steyn J Obstet Gynaecol 2003; 23:150-5 10.1080/014436103000074673 |
| Pitt (Vaginal only), 2001 | not relevant exposure | EXCLUDED: vaginal exposure (included in the Meta-analysis 'Metronidazole (vaginal only)'). |
Pitt Obstet Gynecol 2001; 98:745-50 10.1016/s0029-7844(01)01517-4 |
| Kazy b (Vaginal), 2005 | not relevant exposure | EXCLUDED: vaginal exposure (included in the Meta-analysis 'Metronidazole (vaginal only)'). |
Kazy Eur J Obstet Gynecol Reprod Biol 2005; 123:174-8 10.1016/j.ejogrb.2005.03.016 |
| Kazy a (Vaginal), 2005 | not relevant exposure | EXCLUDED: vaginal exposure (included in the Meta-analysis 'Metronidazole (vaginal only)'). |
Kazy Arch Gynecol Obstet 2005; 272:294-7 10.1007/s00404-005-0003-4 |
| Zarante (Vaginal), 2009 | not relevant exposure | EXCLUDED: vaginal exposure (included in the Meta-analysis 'Metronidazole (vaginal only)'). |
Zarante Int J Pediatr Otorhinolaryngol 2009; 73:1434-7 10.1016/j.ijporl.2009.07.012 |
| Uppal, 1991 | not in pregnancy | EXCLUDED: not related to pregnancy (congenital malformations were reason requiring corrective surgery, with use of different kinds of antibiotics). | |
| Shah, 1998 | not in pregnancy | EXCLUDED: No exposure during pregnancy :'metronidazole after the cord clamp-ing and two further doses of combination therapy at 8 hourly intervals.' |
Shah Int J Gynaecol Obstet 1998; 62:23-9 10.1016/s0020-7292(98)00063-0 |
| Leong, 2019 | not relevant study design | EXCLUDED: Data 'Pregnancies with >= 1 prescription after a pregnancy-related visit' could be used as a proxy of exposure during pregnancy => but could also be exposed during pregnancy and before the pregnancy-related visit => No adequate design. |
Leong PLoS ONE 2019; 14:e0211319 10.1371/journal.pone.0211319 |
| Goldenberg b, 2006 | not relevant outcome | EXCLUDED: outcomes related to antibiotic efficacy rather than safety. No analysis of fetal/neonatal/maternal safety data according to treatment. |
Goldenberg Am. J. Obstet. Gynecol. 2006; 195:1065-74 10.1016/j.ajog.2006.05.046 |
| Harwell, 2003 | not relevant outcome | Study on efficacy of a Buffering Vaginal Microbicide in pregnant women with Bacterial Vaginosis. Subjects with BV at test of cure (after treatment) were offered oral metronidazole. No data on safety fetal/neonate/maternal outcomes. |
Harwell J Womens Health (Larchmt) 2003; 12:255-9 10.1089/154099903321667591 |
| Mitchell 2009b, 2009 | not relevant outcome | EXCLUDED: data on bacterial colonization, proinflammatory cytokines, sialidase, and the protective compound Secretory leukocyte protease inhibitor (SLPI). |
Mitchell J Womens Health (Larchmt) 2009; 18:1817-24 10.1089/jwh.2009.1378 |
| Nelson, 2009 | not relevant outcome | EXCLUDED: Study on the impact of the Prevalence of bacteria and mean concentration of bacteria on the pregnancy outcomes. | |
| Kayihura, 2003 | not relevant outcome | EXCLUDED: outcomes related to antibiotic efficacy rather than safety. No fetal/neonatal/maternal safety data. |
Kayihura Acta Obstet Gynecol Scand 2003; 82:636-41 10.1034/j.1600-0412.2003.00205.x |
| Meyer, 2003 | not relevant outcome | EXCLUDED: outcomes related to antibiotic efficacy rather than safety. No fetal/neonatal/maternal safety data. |
Meyer South. Med. J. 2003; 96:992-5 10.1097/01.SMJ.0000060570.51934.14 |
| Taha, 2006 | not relevant outcome | EXCLUDED: outcomes related to antibiotic efficacy rather than safety. No fetal/neonatal/maternal safety data. |
Taha AIDS 2006; 20:1313-21 10.1097/01.aids.0000232240.05545.08 |
| Lee, 2016 | not relevant outcome | EXCLUDED: outcomes related to antibiotic efficacy rather than safety. No fetal/neonatal/maternal safety data. |
Lee J. Matern. Fetal. Neonatal. Med. 2016; 29:2727-37 10.3109/14767058.2015.1103729 |
| Wawer, 1999 | not relevant outcome | EXCLUDED: outcomes related to antibiotic efficacy rather than safety. No fetal/neonatal/maternal safety data. | |
| Goldenberg, 2007 | not relevant outcome | EXCLUDED: subanalysis of the clinical published by Goldenberg 2005 et Taha 2006, specifically on the impact the Fetal Fibronectin on adverse infant outcomes. |
Goldenberg Obstet Gynecol 2007; 109:392-401 10.1097/01.AOG.0000247628.68415.00 |
| Rauniar, 2006 | not relevant outcome | EXCLUDED: outcomes related to antibiotic efficacy rather than safety and article unavailable. | |
| Shimaoka - Vaginal, 2019 | data not abstractable | EXCLUDED: results only provided in a graph and a p value | |
| Kazy, 2004 | repeat population groups, duplicate reports (most recent study included) | EXCLUDED: data available in a more recent and detailled publication (Kazy 2005a). Metronidazole: n=570 exposures. |
Kazy Int J Gynaecol Obstet 2004; 87:161-2 10.1016/j.ijgo.2004.07.017 |
| Goldenberg, 2001 | same data already obtained by other studies | EXCLUDED: this is a secondary analysis of women included in the article published by Carey 2000. |
Goldenberg Am. J. Obstet. Gynecol. 2001; 185:485-6 10.1067/mob.2001.115998 |
| Kazy 2005c, 2005 | same data already obtained by other studies | EXCLUDED: the same database was used to assess the same outcome, specifically for Metronidazole with distinction between route of exposure (oral: Czeizel 1998 and vaginal: Kazy 2005b). | |
| McDonald, 1997 | same data already obtained by other studies | EXCLUDED: This is an extended abstract of a full paper published in the British Journal of Obstetrics and Gynaecology (McDonald 1997). |
McDonald, H.M. International Journal of STD and AIDS 1997; 8:37-38. 10.1258/0956462971919426 |
| Stringer, 2010 | same data already obtained by other studies | EXCLUDED: subanalysis of the study published by Goldenberg 2006, only among women with treated trichomoniasis. | |
| Sheffield, 2005 | same data already obtained by other studies | EXCLUDED: subanalysis of the clinical trial published by Carey 2000. |
Sheffield Obstet Gynecol 2005; 105:557-62 10.1097/01.AOG.0000153533.13658.c2 |
| Hendler, 2007 | same data already obtained by other studies | EXCLUDED: subanalysis of the 2 clinical trials published by Andrews 2003 and Klebanoff 2001. |
Hendler Am. J. Obstet. Gynecol. 2007; 197:488.e1-5 10.1016/j.ajog.2007.03.073 |
| Kurtzman, 2009 | same data already obtained by other studies | EXCLUDED: secondary analysis of data obtained during the PREMET study (Shennan, 2006). |
Kurtzman Am. J. Obstet. Gynecol. 2009; 200:263.e1-6 10.1016/j.ajog.2009.01.018 |
| Kigozi, 2003 | same data already obtained by other studies | EXCLUDED: subanalysis of the study published by Gray 2001 and Wawer 1999, only among women with Trichomonas. |
Kigozi Am. J. Obstet. Gynecol. 2003; 189:1398-400 10.1067/s0002-9378(03)00777-4 |
| Tita, 2007 | same data already obtained by other studies | EXCLUDED: subgroup analyses of study published by Andrews 2006 to explore whether baseline endometrial microbial colonization and plasma cell endometritis were risk factors for adverse pregnancy outcomes. |
Tita Am. J. Obstet. Gynecol. 2007; 197:367.e1-6 10.1016/j.ajog.2007.06.028 |
| Potter, 2006 | same data already obtained by other studies | EXCLUDED: subanalysis of the study published by Goldenberg 2006, only among women with syphilis. |
Potter Sex Transm Dis 2006; 33:604-9 10.1097/01.olq.0000216029.00424.ae |
| Vermes, 2015 | same data already obtained by other studies | EXCLUDED: Metronidazole plus Miconazole => vaginal. |
Vermes Birth Defects Res. Part A Clin. Mol. Teratol. 2015; 103:804-13 10.1002/bdra.23383 |
| Morgan, 1979 | article unavailable | EXCLUDED: not available. | |
| Oakeshott, 2004 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis performed according to the statut of Bacterial vaginosis (positive or negative), without analysis or data according to treatments. |
Oakeshott P British Journal of General Practice 2004; 54:119- |
| Psomiadis, 2005 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: no distinction between treatments. |
Psomiadis J. Matern. Fetal. Neonatal. Med. 2005; 18:47-52 10.1080/14767050500073142 |
| Sevene, 2012 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: No distinction between substances, no specific data for metronidazole. |
Sevene Paediatr Drugs 2012; 14:43-9 10.2165/11591270-000000000-00000 |
| Mosha, 2014 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Fetal outcomes provided for 'Antimalarial and antibiotics exposure in relation to pregnancy (n = 994)', without distinction between treatment. |
Mosha BMC Pregnancy Childbirth 2014; 14:322 10.1186/1471-2393-14-322 |
| Subtil, 2002 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: case-control study on bacterial vaginosis but without distinction between the antibiotic treatment (4 out of 14 patients with clinical signs of vaginosis treated with antibiotic (metronidazole)). | |
| Shariatzadeh, 2006 | Studies without separate analysis of the considered drug/class from other drugs/class | Some fetal/neonate/maternal safety data were reported (no anomaly was detected among newborns) but no distinction between the different types of antibiotics (28 patients received nine different types of antibiotics). |
Shariatzadeh Am. J. Med. 2006; 119:872-6 10.1016/j.amjmed.2006.01.014 |
| Honda, 2014 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: In the intervention group: no distinction between women treated with vaginal metronidazole (250 mg) for 7 days within 4 weeks after the screening test) and untreated women. | |
| Kiss, 2010 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: no distinction between treatment groups (clindamycin, clotrimazole, metronidazole). |
Kiss Eur. J. Obstet. Gynecol. Reprod. Biol. 2010; 153:38-42 10.1016/j.ejogrb.2010.06.020 |
| Jacobsson, 2002 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis was performed for antibiotics (mainly erythromycin, penicillin V, pivmecillinam and nitrofurantoin) but not for antimycotic drugs (econazol, clotrimazol, metronidazol or tinidazol) during pregnancy. |
Jacobsson Acta Obstet Gynecol Scand 2002; 81:1006-10 10.1034/j.1600-0412.2002.811103.x |
| Kankuri, 2003 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: the analysis were performed for the sepsis group without distinction between treatment ('a combination of cefuroxime and metronidazole was used in 80% (33/41) of the mother with sepsis'). |
Kankuri Acta Obstet Gynecol Scand 2003; 82:730-5 10.1034/j.1600-0412.2003.00265.x |
| McQueen, 2014 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of Chronic endometritis group versus No chronic endometritis group, without distinction between treatments in the Chronic endometritis group. |
McQueen Fertil. Steril. 2014; 101:1026-30 10.1016/j.fertnstert.2013.12.031 |
| Mercer, 1999 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: no distinction between antibiotics used during pregnancy and maternal/neonate risk. |
Mercer Am. J. Obstet. Gynecol. 1999; 181:816-21 10.1016/s0002-9378(99)70307-8 |
| Lopez, 2002 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: antibiotics analyzed as a whole, without distinction between treatments (metronidazole, clotrimazole, or nistatine). |
Lopez J. Periodontol. 2002; 73:911-24 10.1902/jop.2002.73.8.911 |
| Vanukuru, 2019 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: outcomes according to maternal outcomes, without distinction between antibiotic treatments. |
Vanukuru J. Matern. Fetal. Neonatal. Med. 2019; 32:1931-1937 10.1080/14767058.2017.1421933 |
| Mueller, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: oral antibiotic prescriptions studied as a whole, without distinction between treatments. | |
| Novakov, 2015 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: antimicrobial therapies (neomycin/polymyxin B/nystatin, metronidazole or miconazole vaginal tablets) studied as a whole, without distinction between treatments. |
Novakov Mikic Arch. Gynecol. Obstet. 2015; 292:371-6 10.1007/s00404-015-3638-9 |
| Knowles, 2015 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: no analysis according to treatment. | |
| Roberts, 2000 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: antibiotics studied as a whole, without distinction between treatments. |
Roberts Aust N Z J Obstet Gynaecol 2000; 40:377-84 10.1111/j.1479-828x.2000.tb01165.x |
| Sagindykova, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of chronic pyelonephritis treated (main group) versus not treated (comparison group), without distinction between treatments. |
Sagindykova, A.A. Biomedical and Pharmacology Journal 2017; 10:535-547. 10.13005/bpj/1139 |
| Skrablin, 2008 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: The prophylactic use of antibiotics was studied as a whole, without distinction between treatments. |
Skrablin Int J Gynaecol Obstet 2008; 102:12-8 10.1016/j.ijgo.2008.02.008 |
| Sungkar, 2012 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: active model group versus control. In the active model group, some women (those diagnosed with BV) received metronidazole. No specific analysis of pregnant women exposed to metronidazole. |
Sungkar Int J Gynaecol Obstet 2012; 117:264-7 10.1016/j.ijgo.2012.01.007 |
| Lacroix, 2007 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: metronidazole included in the urino-genital class of medicines, without analysis according to substances. | |
| Yoon, 2019 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of 'Use of ceftriaxone, clarithromycin and metronidazole' as a whole, without distinction between treatments. |
Yoon Am J Obstet Gynecol 2019; 221:142.e1-142.e22 10.1016/j.ajog.2019.03.018 |
| Venkatesh, 2020 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of 'Clindamycin or metronidazole' exposure without distinction between the 2 treatments. |
Venkatesh Am J Obstet Gynecol MFM 2020; 2:100074 10.1016/j.ajogmf.2019.100074 |
| Czeizel, 2009 | Review articles, letter to editor, editorial, comments | EXCLUDED: not original data (data related to metronidazole published by Kazy 2005). |
Czeizel Expert Opin Drug Saf 2009; 8:283-303 10.1517/14740330902916459 |
| Kumar,, 2014 | pattern of exposure | EXCLUDED: only pattern of exposure for metronidazole (no data on the fetal/maternal/neonatal outcomes). | |
| Das, 2016 | pattern of exposure | EXCLUDED: study on pattern of exposure, without fetal/maternal/neonate safety data. | |
| Kabuluzi, 2014 | pattern of exposure | EXCLUDED: study on pattern of exposure, without fetal/maternal/neonate safety data. |
Kabuluzi J. Matern. Fetal. Neonatal. Med. 2014; 27:1204-8 10.3109/14767058.2013.860439 |
| Daw, 2012 | pattern of exposure | EXCLUDED: study on pattern of exposure, without fetal/maternal/neonate safety data. |
Daw Clin Ther 2012; 34:239-249.e2 10.1016/j.clinthera.2011.11.025 |
| Doubova, 2014 | pattern of exposure | EXCLUDED: Assessment of the 'Percentage of pregnant women diagnosed with bacterial vaginosis or trichomoniasis, who had vaginal metronidazol prescription in adequate doses and duration', without data on fetal/neonate/maternal safety outcomes. |
Doubova BMC Pregnancy Childbirth 2014; 14:168 10.1186/1471-2393-14-168 |
| Fonseca, 2002 | pattern of exposure | EXCLUDED: data on pattern of exposure, without data on maternal/fetal/neonate safety outcomes. |
Fonseca Rev Saude Publica 2002; 36:205-12 10.1590/s0034-89102002000200013 |
| Palmsten, 2015 | pattern of exposure | EXCLUDED: pattern of prescription without safety data on fetal/neonate/maternel outcomes. |
Palmsten Obstet Gynecol 2015; 126:465-73 10.1097/AOG.0000000000000982 |
| Kureshee, 2013 | pattern of exposure | EXCLUDED: pattern of exposure without safety data on fetal/neonatal/maternal outcomes. |
Kureshee J Clin Diagn Res 2013; 7:2470-4 10.7860/JCDR/2013/6329.3582 |
| Santos 2012a, 2012 | pattern of exposure | EXCLUDED: pattern of exposure without safety fetal/neonatal/maternal outcomes. | |
| Wagner, 2006 | pattern of exposure | EXCLUDED: pattern of exposure, without data on safety fetal/neonate/maternal outcomes. |
Wagner Pharmacoepidemiol Drug Saf 2006; 15:369-86 10.1002/pds.1193 |
| Rouamba, 2018 | pattern of exposure | EXCLUDED: pattern of exposure without data on maternal/fetal/neonatal outcomes. |
Rouamba Drugs Real World Outcomes 2018; 5:193-206 10.1007/s40801-018-0141-1 |
| Sarangarm, 2012 | pattern of exposure | EXCLUDED: pattern of exposure without data on maternal/fetal/neonatal outcomes. |
Sarangarm Birth Defects Res. Part A Clin. Mol. Teratol. 2012; 94:153-61 10.1002/bdra.22888 |
| Yusuff, 2011 | pattern of exposure | EXCLUDED: pattern of exposure and risk perception, without data on maternal/fetal/neonatal outcomes. |
Yusuff Int J Clin Pharm 2011; 33:868-75 10.1007/s11096-011-9556-4 |
| Jules, 2010 | pattern of exposure | EXCLUDED: pattern of exposure, without maternal/fetal/neonatal safety outcomes. |
Jules Acad Pediatr. 2010 Nov-Dec;10(6):395-399. 10.1016/j.acap.2010.09.003 |
| Morales, 1994 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Morales Am. J. Obstet. Gynecol. 1994; 171:345-7; discussion 348-9 10.1016/s0002-9378(94)70033-8 |
| Mann a, 2009 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Mann J Womens Health (Larchmt) 2009; 18:493-7 10.1089/jwh.2008.0964 |
| Bergstrom, 1991 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Bergstrom Gynecol. Obstet. Invest. 1991; 32:217-9 10.1159/000293035 |
| Shennan, 2006 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Shennan BJOG 2006; 113:65-74 10.1111/j.1471-0528.2005.00788.x |
| Klebanoff, 2001 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Klebanoff N. Engl. J. Med. 2001; 345:487-93 10.1056/NEJMoa003329 |
| Carey, 2005 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Carey Am. J. Obstet. Gynecol. 2005; 192:1341-6; discussion 1346-7 10.1016/j.ajog.2004.12.069 |
| Gray, 2001 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Gray Am. J. Obstet. Gynecol. 2001; 185:1209-17 10.1067/mob.2001.118158 |
| Norman, 1994 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Norman Br J Obstet Gynaecol 1994; 101:404-8 10.1111/j.1471-0528.1994.tb11912.x |
| Moniri, 2009 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. | |
| Carey, 2000 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Carey N. Engl. J. Med. 2000; 342:534-40 10.1056/NEJM200002243420802 |
| Goldenberg, 2006 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Goldenberg Am. J. Obstet. Gynecol. 2006; 194:650-61 10.1016/j.ajog.2006.01.004 |
| Hauth, 2001 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Hauth American Journal of Obstetrics and Gynecology 2001;185(6):S86. |
| Hauth, 1995 | efficacy rather than safety aims | EXCLUDED: Study related to an acute pathology of the pregnancy, where the outcomes were studied to establish the efficacy of treatment rather than safety, thus not reported in metaPreg. |
Hauth N. Engl. J. Med. 1995; 333:1732-6 10.1056/NEJM199512283332603 |
| McDonald, 1997 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
McDonald Br J Obstet Gynaecol 1997; 104:1391-7 10.1111/j.1471-0528.1997.tb11009.x |
| Odendaal, 2002 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. | |
| Sen, 2005 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. | |
| Darwish, 2007 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Darwish J. Obstet. Gynaecol. Res. 2007; 33:781-7 10.1111/j.1447-0756.2007.00656.x |
| Ekdahl, 2021 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of azole in an obstetrical indication, including only the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here. |
Ekdahl Eur J Obstet Gynecol Reprod Biol 2021; 265:90-95 10.1016/j.ejogrb.2021.08.019 |
-
About
-
Master protocol
-
Browse exposition
-
RSS
-
Made with in Lyon
-
Contact us
-
Privacy policy
-
